Oral v. pulse intravenous cyclophosphamide: A retrospective analysis of adverse events in a setting with a high burden of infectious disease

Abstract

Background. Cyclophosphamide (CPM) is still considered to be the first-line treatment for many life-threatening autoimmune conditions. It does, however, carry a significant risk of serious adverse events, especially infections. At present CPM is administered as either a daily oral dose (DOC) or an intravenous pulse (PIVC). There is uncertainty regarding the safety profiles of both regimens in settings with a high burden of infectious diseases. Objective. To compare the frequency and nature of adverse events related to the use of DOC and PIVC in such a setting. Methods. A cohort of patients treated with CPM for autoimmune diseases at Tygerberg Academic Hospital, Cape Town, South Africa, from 1 January 2008 to 31 May 2013 was studied. We compared participants receiving DOC and PIVC with regard to disease characteristics and the occurrence of major adverse events. Results. A total of 134 participants (92 DOC and 42 PIVC) were included. Participants in the DOC group were treated for longer (174 v. 101 days; p<0.01) and with higher cumulative doses (17 276 v. 3 327 mg; p<0.01). Risk of infection was similar in the two groups, although there were 6 deaths from leucopenic sepsis in the DOC group (v. 0; p=0.18). Nadir leucocyte counts were also lower in the DOC group (median 3.8 v. 5.3 × 10

Cyclophosphamide Pulse Therapy in the Treatment of Systemic Sclerosis Associated Interstitial Lung Disease: An Observational Study

“…All the previous studies also demonstrated that intravenous pulse cyclophosphamide therapy was associated with lower adverse events compared to oral cyclophosphamide. 15,16 It is also possible that proper hydration of the patient during the pulse therapy reduced adverse events.…”

Clinico-pathological features of repeat renal biopsies in patients with lupus nephritis at Groote Schuur Hospital, Cape Town

“…The oral Cyclophosphamide regimen is not favoured because it is associated with longer treatment duration, greater cumulative doses and more severe leucopenia. 41 • The Euro Lupus regimen which uses less doses of cyclophosphamide is not favoured in Africa where the disease is much more severe compared to the population in the Euro Lupus study. 10,29,42 All regimens IV Methylprednisolone in severe cases followed by oral prednisolone 0.5-1mg/kg tapered over 6 to 12 months according to clinical response…”